Recent advances in science enable novel therapies to treat and reverse fibrosis

Fibrosis is central to multiple diseases as well as several life-threatening cancers such as hepatocellular carcinoma and cholangiocarcinoma.

Alentis is building on the discovery that Claudin-1 (CLDN1) is a novel, previously unexplored target with a unique mechanism of action in the pathology of fibrosis and carcinogenesis. Alentis is exploiting the functional role of CLDN1 and its associated pathways in disease biology to develop breakthrough therapies for fibrotic diseases and associated cancers. These include liver and kidney disease as well as hepatobiliary cancer. Moreover, Alentis is building on a unique platform that models the clinical cell circuits of liver disease progression and cancer in state-of-the-art human cell-based systems. This platform is combined with single cell RNASeq of patient liver tissues having uncovered drug candidates in collaboration with the University of Strasbourg and Inserm, the Mount Sinai Hospital and University of Texas Southwestern (UTSW). Using this cutting-edge platform based on clinically relevant read-outs and patient tissues, Alentis is discovering new targets and developing new medicines for treatment of fibrosis and advanced liver disease – a key unmet medical need rising world-wide.

Therapeutic pipeline

  • ALE-F02, CLDN1 mAb for Liver Fibrosis (F3/F4), with silenced effector function
  • ALE-C04, CLDN1 mAb for Hepatocellular Carcinoma (HCC) and Cholangiocarcinoma (CC), with an effector function targeting directly the cancer and at the same time the underlying fibrotic liver disease (dual effect on cancer and liver disease)

Alentis is using its portfolio of unique anti-CLDN1 monoclonal antibodies (mAbs) that binds to CLDN1 expressed on the cell membrane of liver myofibroblasts and the basolateral membrane of hepatocytes to develop a pipeline of novel mechanisms for fibrosis in late stage preclinical development:

Alentis aims to initiate clinical studies in 2021 for fibrosis and in 2022 for fibrosis-driven liver cancer, with Proof of Concept results expected by 2023 and 2024.

Discovery programs

Alentis is widening its therapeutic reach to explore the potential of targeting CLDN1 in fibrosis of other tissues, including kidney where CLDN1 dysregulation is an established driver of the disease.

In addition, we are using our proprietary drug discovery platform for future pipeline expansion, pioneering a new approach to the screening and identification of novel targets, biomarkers and clinical candidates for advanced liver disease and cancer.